Five highlights of the pharmaceutical industry in 2017
Release time:
2020-08-14
2017 NPC and CPPCC Five Major Points in Pharmaceutical Industry
3# September 3 , 2017 NPC and CPPCC will be held in Beijing. The issues and decisions of the NPC and CPPCC will directly affect the overall trends and trends of the industry in the following year and have a profound impact on the future economy and major assets. The following is a summary of the highlights of 5 in the pharmaceutical industry during the 2017 NPC and CPPCC sessions.
1 , Supply-side Reform: Value Chain Distribution Faces Reconstruction
The so-called supply-side reform is to promote the development of economic industry by liberating productivity from the supply and production sides. As early as last year's Spring Festival, the State Council meeting focused on the pharmaceutical industry and proposed measures such as "aiming at the urgent needs of the masses, improving the safety evaluation and product traceability system, combining the" three medical "linkage reform, and building a pharmaceutical circulation network throughout the township", hoping to promote the innovation and upgrading of the pharmaceutical industry through supply-side reform. From
to this year, the health planning Commission held a press conference on 2 8 , saying that through the implementation of the "action plan to further improve medical services", the service process has been continuously optimized, the medical quality has been continuously improved, the service mode has been continuously innovated, and the doctor-patient relationship has been continuously harmonious. 2017 The Health Planning Commission and the State Administration of Traditional Chinese Medicine have identified 11 key tasks to further improve medical services, including expanding the real-name appointment diagnosis and treatment pilot.
In addition, the General Office of the State Council issued a blockbuster document entitled "Several Opinions on Further Reforming and Improving Drug Production, Circulation and Use Policies" on 2 January 9 , which aroused strong repercussions in the pharmaceutical industry. The "opinion" points out that starting from the three major links of drug production, circulation and use is an important reform document covering the entire pharmaceutical industry chain, which will play a key role in further promoting the supply-side structural reform of the pharmaceutical industry. it will also have a far-reaching impact on the future healthy development of the pharmaceutical industry.
If 2016 is the year of supply-side reform, then 2017 will be the year of deepening the supply-side reform of medical reform. Supply-side structural reform has become the key word of this year's "two sessions" medicine.
2 , medical reform: the formation of a basic medical and health system framework
medical reform has always been a hot issue of concern. the key work points of 2017 published by the health planning Commission proposed that the medical reform should be continuously deepened and the formation of a basic medical and health system framework should be accelerated. These include measures such as promoting the hierarchical diagnosis and treatment system, accelerating the establishment of a modern hospital management system, and implementing the reform of the drug supply guarantee system. In addition, medical reform has also been mentioned in the government work reports of the local two sessions that have been implemented, and various localities have "bright moves" to solve the problem of people seeing a doctor ".
Zhejiang Province has achieved "double sinking and two upgrading" of medical resources through the establishment of a medical consortium, alleviating the current situation of people's difficulty in seeing a doctor, and accelerating the reform of "Internet + medical prices.
medical reform has always been one of the key reform projects promoted by the State Council. Deepening the reform of the medical and health system and strengthening the construction of the medical service system will become the focus of attention and heated discussion among the representatives of the two sessions.
3 , medical and nursing integration: make up for shortcomings and solve the pension problem
With the increasing aging of the population, new requirements have been put forward for the development of medical care. In the "Several Opinions on Accelerating the Development of Elderly Care Services" issued by the State Council in 2013 , it was proposed to "promote the integrated development of medical care and elderly care", which pointed out the direction for the development of my country's elderly care industry. This year, Zhejiang proposed to actively promote the reform of the old-age insurance system, study and formulate a linkage adjustment mechanism for the basic pension for retirees and the minimum standard of basic pension for urban and rural residents, and steadily raise the standards of basic pension and basic pension.
At the National Two Sessions, elderly care has become an issue of high concern, and the quality of life of the elderly in their later years will affect the stability of the entire society. How to improve the quality of elderly care services has received special attention.
4
, Pollution Control: Hundreds of pharmaceutical companies may face suspension of production. Environmental protection has always been a topic of close attention throughout the country. According to the data of the legal network voting system, as of 2017
2 April 28 , smog control ranked among the top 10 hot spots of the NPC and CPPCC with 19598 votes. 2017 is the second year of the 13th Five-Year Plan and a key year for environmental protection. Last year in the middle and late of December 1, there was a large-scale continuous severe air pollution in our country. Satellite monitoring shows that the scope of smog was once expanded to 17
provinces, autonomous regions and municipalities in, covering an area of 142 .09 million square kilometers, that is to say, more than 1/7 of the country was shrouded in smog. With such a "power" of the haze, naturally become the focus of attention of the various provinces. It is no longer news to use ten "haze" volts to describe the weather in Beijing-Tianjin-Hebei region during winter heating. However, after the Spring Festival this year, the "Beijing-Tianjin-Hebei and Surrounding Areas Air Pollution Prevention and Control Work Plan for 2017
(Draft for Comments ) " ( hereinafter referred to as "Plan" ) once again pushed pharmaceutical companies in the region to the forefront. If this "plan" becomes a reality, hundreds of pharmaceutical enterprises in "2+26 " cities such as Beijing, Tianjin, Shijiazhuang, Jinan, Zhengzhou and Taiyuan will not be allowed to produce for 120 days throughout the year. According to the implementation promotion plan of ( Ten Atmospheric Articles
)issued by the State Council in 2013 , 2017 is the final assessment year of the action plan. Environmental protection has naturally become one of the hot words of the two sessions this year.
, Reform of State-owned Enterprises: Mixed Reform of Pharmaceutical Enterprises Station in UpportSince 2016
, various regions have successively issued a number of special supporting documents to implement the "Guiding Opinions on Deepening the Reform of State-owned Enterprises" promulgated and implemented by the CPC Central Committee and the State Council, and the "four beams and eight pillars" of the reform of state-owned enterprises have risen, accelerate from "design" to "construction".1 Since September, the local two sessions have been intensively held, and the reform of state-owned enterprises has once again become the focus of the local "two sessions. 2016
# Decemberth June 29 , Yunnan Baiyao controlling shareholder Baiyao Holdings introduced about 254 billion yuan to Xinhuadu Industrial Group Co., Ltd. through capital increase. Baiyao Holding's equity structure was changed to Yunnan SASAC and Xinhuadu each holding 50% equity. At present, the company's core business consists of the provincial pharmaceutical company, the pharmaceutical division, the health products division and the traditional Chinese medicine resources division, which are respectively responsible for the four major business sectors of pharmaceuticals, health daily chemical products, traditional Chinese medicine resources products and pharmaceutical commerce. The initial completion of the mixed reform plan of Baiyao Holdings has made Yunnan Baiyao a model of performance growth in the pharmaceutical industry. Since the listing of in 1993 , Yunnan Baiyao has led its peers in performance growth. Compared with listed companies under state-owned enterprises in Yunnan Province, Yunnan Baiyao's return on net assets and other indicators are also far ahead. In the report on accelerating the reform of state-owned enterprises recently released by the Tianjin State-owned Assets Supervision and Administration Commission, the timetable and roadmap for Tianjin Pharmaceutical Group Co., Ltd. to promote the reform of state-owned enterprises clearly emerged. Among them, increasing the intensity of mixed reform, using the listing platform to achieve asset securitization and improving the assessment and incentive mechanism have become the three highlights. Some pharmaceutical industry analysts pointed out that from the perspective of the reform route, Tianyao Group has continued the overall thinking of the current state-owned enterprise reform. It is another typical case of initiating the reform of state-owned enterprises in the pharmaceutical industry after Yunnan Baiyao.
pharmaceutical enterprise reform results show, the company's profitability and overall value has been further improved. On the basis that the top-level design of the reform of state-owned enterprises has been basically completed, the reform of pharmaceutical state-owned enterprises will gradually reach a climax in 2017
, which will affect the future direction of pharmaceutical investment to a certain extent. (article from the network)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11